Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 29;165(6):bqae051.
doi: 10.1210/endocr/bqae051.

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies

Govinda R Hancock  1 , Jason Gertz  2 , Rinath Jeselsohn  3   4   5 , Sean W Fanning  1
Affiliations
Review

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies

Govinda R Hancock et al. Endocrinology. .

Abstract

Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the prominent nuclear receptor expressed in ∼80% of BCa. However, up to ∼50% of patients who are ER+ with high-risk disease experience post endocrine therapy relapse and metastasis to distant organs. The vast majority of BCa mortality occurs in this setting, highlighting the inadequacy of current therapies. Genomic abnormalities to ESR1, the gene encoding ERα, emerge under prolonged selective pressure to enable endocrine therapy resistance. These genetic lesions include focal gene amplifications, hotspot missense mutations in the ligand binding domain, truncations, fusions, and complex interactions with other nuclear receptors. Tumor cells utilize aberrant ERα activity to proliferate, spread, and evade therapy in BCa as well as other cancers. Cutting edge studies on ERα structural and transcriptional relationships are being harnessed to produce new therapies that have shown benefits in patients with ESR1 hotspot mutations. In this review we discuss the history of ERα, current research unlocking unknown aspects of ERα signaling including the structural basis for receptor antagonism, and future directions of ESR1 investigation. In addition, we discuss the development of endocrine therapies from their inception to present day and survey new avenues of drug development to improve pharmaceutical profiles, targeting, and efficacy.

Keywords: ESR1; ERα antagonism; breast cancer; endocrine therapy; hotspot mutations; structural variants.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. - PubMed
    1. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524‐541. - PubMed
    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288‐300. - PubMed
    1. Goldstein SR. Selective estrogen receptor modulators and bone health. Climacteric. 2022;25(1):56‐59. - PubMed
    1. Wardell SE, Yllanes AP, Chao CA, et al. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Res Treat. 2020;179(1):67‐77. - PMC - PubMed

Publication types

Substances